Investor Relations · 2026

Инвесторам

Nightbox LLC поднимает pre-seed round в Q3 2026, чтобы fund in vivo validation across трёх syngeneic murine tumor models, wet-lab scientific lead hire и FDA pre-IND briefing book. Текущий stage — computational only — в vivo или clinical data ещё. Follow-on seed откроется после wet-lab validation. Full data room по запросу.

Условия раунда (target)

Round	Pre-seed
Target close	Q3 2026 (pre-seed); follow-on seed targeted post-in-vivo (H1 2027)
Target raise	$3M – $5M (pre-seed)
Use of proceeds	In vivo validation, 3 syngeneic models (≈60%) · wet-lab scientific lead hire (≈20%) · pre-IND meeting prep (≈15%) · regulatory consultant (≈5%)
Cap table	100% founder-owned. $0 raised до текущего момента. Zero prior outside capital.
Current evidence	Computational only. AlphaFold/Rosetta structural validation, PK-PD model, MICA/B selectivity atlas. Zero in vivo, zero human, zero peer-reviewed data yet.
Exit thesis	Strategic acquisition US pharma post-Phase 2

Три pillar'а compound друг друга

Инвесторы usually back one thesis at a time. Nightbox runs три deep-tech pillar'а на shared substrate, each de-risking others:

🧬 Biotech	NKG2D-LIF6 chimera. Provisional patent filed. Strategic-acquisition exit thesis.
⚡ Compute	UniGPU runtime. 47 TFLOP/s WMMA на consumer AMD. SBIR Phase II / DARPA / DIU transition path.
🦆 AI agent	SilverDuck local-first stack. NB-R14B LLM (Apache 2.0). USAF SBIR DAF26BX02-NV501 match.
🛡️ Bridge	Liaison Framework v2.3 — двусторонняя editorial доктрина US ↔ РФ. Anti-state-capture симметрично. Транспарентная business-liaison архитектура. Federal-recognition path через transparent disclosure.

Capital, deployed к any single pillar, materially improves остальные (shared compute, shared infrastructure, shared compliance posture). Pre-seed fundable на одном биотехе; Liaison Framework + UniGPU — asymmetric upside.

Почему сейчас

NKG2D-targeted oncology clinically validated — Fate Therapeutics has IND clearance для FT536; multiple Phase I trials show signal.
Single-construct gene therapy обходит CAR-T manufacturing complexity entirely.
Чистая intellectual property whitespace на specific NKG2D-LIF6 chimera.
AI-augmented R&D operating model — production Claude-based agent stack на Vercel Edge, AlphaFold3 + RoseTTAFold structural pipeline, PyMOL + SnapGene construct design, custom prompt-router с NFKC normalization и 22-pattern injection scanner. Methods и code public под CC BY 4.0.
Federal procurement environment в 2026 favors domestic dual-use biotech с national security relevance.
Federal-stack ready: SAM.gov Active с 2026-05-18, CAGE 20BA7 (DLA Battle Creek), DSIP firm registered, NIH eRA Commons institution submitted.

Public traction artifacts

Каждое claim ниже independently verifiable from public URL. Zero data-room access required.

SAM.gov Active (UEI UHCAB6UXXKF2) — verifiable at sam.gov
CAGE Code 20BA7 — DLA Battle Creek assigned 2026-05-17, public lookup cage.dla.mil
Liaison Framework v2.3 — /ru/liaison-framework + canonical .json
Market Re-Entry Roadmap v1.0 — 14+ западных компаний maintaining IP в Rospatent через 2025
Wikidata cross-attestation — organization Q139590659, founder Q139590669, NKG2D-LIF6 chimera Q139590736
14B-parameter NB-R14B LLM (Apache 2.0) — proprietary in-house weights для SilverDuck pillar
Open source на github.com/nightbox-llc — Apache 2.0 (code) + CC-BY-4.0 (doctrine)

Materials по запросу

Seed deck (current version)
Full freedom-to-operate analysis
In silico validation report and methods
Construct architecture and selectivity model
Provisional patent draft (under NDA)
Financial model and use-of-proceeds breakdown
Founder background and references

Public materials

Получить data room

Отправь brief note (firm, focus areas, ticket size, lead-vs-follow) на investors@nightboxllc.com. Мы typically share access within 24 часа и follow up to schedule a 30-minute working call.